Does rituximab increase the incidence of infectious complications? A narrative review.
about
Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive ReviewAlterations in mouse hypothalamic adipokine gene expression and leptin signaling following chronic spinal cord injury and with advanced ageLeveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States.Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.Serologic vaccination response after solid organ transplantation: a systematic review.Immunoglobulin replacement therapy in secondary hypogammaglobulinemiaInfections in patients taking Rituximab for hematologic malignancies: two-year cohort study.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates.Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge.Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host diseaseReview article: BK virus in systemic lupus erythematosusTreatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient.Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models.Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificitiesCytomegalovirus infection in childhood-onset systemic lupus erythematosus.Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?Biologics in oral medicine: principles of use and practical considerations.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolA retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.B cells participate in tolerance and autoimmunity through cytokine production.Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.Emerging immunological drugs for chronic lymphocytic leukemia.Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Late-onset neutropenia after rituximab in ANCA-associated vasculitis.Infectious complications of rituximab therapy in renal disease.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab.ABO desensitization affects cellular immunity and infection control after renal transplantation.Characterization of the B cell response to Leishmania infection after anti-CD20 B cell depletion.Cellular immunotherapy with ex vivo expanded cord blood T cells in a humanized mouse model of EBV-associated lymphoproliferative disease.Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?
P2860
Q26773178-86B6A883-15D8-45F6-9732-06D8230A21D5Q27333098-BC0AD9F0-878E-475E-B15C-7B78B08DD3D1Q30583310-D3026F75-0BEE-4308-BB61-E05F75B7C66CQ34481015-E09DA5BE-8880-4C29-BD04-5E92D11817BCQ34602836-F7BBD332-745F-4744-AE4C-FD4D1A843B32Q34652046-B8934038-87CB-49FF-9104-9C69B813C61EQ34815753-608FCD38-F239-4982-B558-E4B80572FB42Q35237511-6FEFA271-B99F-4A00-BE8B-C6DE80389AD8Q35531873-5C942AEA-59E7-4CF6-812B-385243F68CE6Q35613669-53167363-2181-4CCF-9128-87503B0CD238Q35664634-DEA94011-C084-4F68-9DB5-5600D395A0C1Q35818013-E5E7F4AF-AFE7-4CF1-ADF3-09D30F97A10FQ35930604-99184F28-EC06-426E-85C1-0CE8120A7FB0Q35986282-FCD10023-D894-4A43-9A65-556E5CA87FBFQ36727762-F1F0C116-E41B-4ACD-A284-8BE59FEB8BA1Q36779863-2FD72F21-A3F7-4FEC-A0DD-61F7A0D3C031Q36992735-42A90DEA-EDA1-46A3-8BF4-141368BDFBFAQ37319382-59D0EBA6-459A-4D8A-BCB8-FA8F9D9C5B8EQ37577044-34F5A4AE-371E-4B0E-8D80-C7072E44AB39Q37912214-A71A7A37-095D-4899-8F71-2E80D970CF38Q37993932-C9A14C6F-4078-42C3-92E0-44A42298E18EQ38081793-26896F53-42DB-49B4-87CC-194431CB887CQ38153099-F55C8030-E3A8-4CF0-B848-0148B42AF25CQ38154934-7BB0D85C-A4D5-455D-A928-04C6F3B03CF7Q38163603-C632716C-08BA-4EDB-9A75-420610E872DEQ38207970-4FA12CBC-B9C8-42BE-A19C-2D8DF6D09937Q38543771-C5E8DF6F-29A7-4561-A48B-0BE6740AA648Q38703120-AF4919F8-E59E-4717-9E30-736F5A947F2DQ38824182-A82DA204-C71D-4026-8B05-EFC6CD24786AQ39215476-46B87937-A133-4973-9864-1D9CDC1E04C6Q39264020-1DCA8514-4BAD-4F1D-9A51-F642E026F9A7Q39944154-70077B5E-9FE9-439E-89D6-E607B40990E8Q40065728-18DEEBA8-E732-47AC-9BA7-E7CC5EA0AB2EQ40097140-D056CB4E-BA80-4E3A-8DC6-B07377BBE3C2Q40302214-DA643A0E-F7F8-4864-AA68-8E7C4CA6CEC2Q40355386-B5DA70DB-7A3A-43C1-8CC8-91BCBAD08BEAQ40879749-D0607C64-7B3A-4FEC-869C-34E1D80645E6Q41059758-71ACF5F8-B56F-4585-ACEA-48D5B1640D72Q41281408-4CAFDB4B-A497-4301-B046-38CAB21432BFQ42229459-CE0D2052-7E30-4666-9D58-FB977C677156
P2860
Does rituximab increase the incidence of infectious complications? A narrative review.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Does rituximab increase the incidence of infectious complications? A narrative review.
@en
Does rituximab increase the incidence of infectious complications? A narrative review.
@nl
type
label
Does rituximab increase the incidence of infectious complications? A narrative review.
@en
Does rituximab increase the incidence of infectious complications? A narrative review.
@nl
prefLabel
Does rituximab increase the incidence of infectious complications? A narrative review.
@en
Does rituximab increase the incidence of infectious complications? A narrative review.
@nl
P1476
Does rituximab increase the incidence of infectious complications? A narrative review.
@en
P2093
Dimitrios Boumpas
George Daikos
P356
10.1016/J.IJID.2010.03.025
P577
2010-11-11T00:00:00Z